Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
Article
[키워드] acute respiratory syndrome
Administered
Adults
adverse event
AEs
age
Analysis
assessment
assigned
BNT162b2
BNT162b2 mRNA
BNT162b2 mRNA vaccine
China
Chinese
clinical trial
Complete
Completed
conducted
coronavirus
COVID-19
development
dose
double-blind
Efficacy and safety
enrolled
Follow-up
geometric mean titer
GMT
GMTs
Han Chinese
healthy
immune response
immunogenicity
immunogenicity endpoint
Inc
independent
individual
injection
intramuscular
Intramuscular injection
investigators
Laboratory parameters
management
messenger
Messenger RNA
Mild
moderate
mRNA vaccine
Neutralising Antibodies
neutralising antibody
of BNT162b2
participant
Participants
pharmaceutical
Placebo
placebo-controlled trial
randomisation
randomised
Randomly
reactogenicity
receive
recipients
recruited
reduced
remained
reported
resolved
Result
robust
Safety
SARS-CoV-2
SARS-CoV-2 variant
SCR
second dose
sera
serious AE
seroconversion rate
severity
Shanghai
Sponsor
statisticians
stratified
T-cell Response
the placebo group
Tolerability
Treatment
Trial
utilised
vaccination
vaccine administration
were blinded
[DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article